Interestingly, EMT has been inversely correlated with the response of cancers to EGFR-targeted therapy and the TGFβ-mitogen-inducible gene 6-miR200 network orchestrates the EMT-associated kinase switch hat induces resistance to EGFR inhibitors in primary tumor xenografts of patient-derived lung and pancreatic cancers carrying wild type EGFR [168]. This evidence concerns the gene EGFR and neoplasm.